| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
alpha-Glucosidase (IC50: 0.169 mg/mL, approximately 775 uM based on MW 218.25)
|
|---|---|
| ln Vitro |
In vitro enzyme assays demonstrate that alpha-Glucosidase-IN-35 is a potent inhibitor of alpha-glucosidase with an IC50 value of 0.169 mg/mL. Based on its molecular weight (218.25 g/mol), this corresponds to approximately 775 uM. The compound is a chromene (a benzopyran derivative) and is also known as 1-(5-hydroxy-2,2-dimethylchromen-6-yl)ethanone. No other specific biological activities (e.g., antioxidant, anti-inflammatory, cytotoxicity) have been reported for this compound. The chromene scaffold is known for diverse biological activities including anti-inflammatory and anticancer properties.
|
| ln Vivo |
No specific in vivo data available for alpha-Glucosidase-IN-35. As an alpha-glucosidase inhibitor with potent activity (IC50 0.169 mg/mL), it has significant potential for postprandial blood glucose reduction in animal models of diabetes and could be a candidate for in vivo efficacy studies. However, published in vivo studies have not been reported. The compound is isolated from Brickellia cavanillesii, a plant used in traditional medicine, suggesting potential ethnopharmacological relevance.
|
| Enzyme Assay |
Recombinant or yeast alpha-glucosidase enzyme (commercial source) is incubated with varying concentrations of alpha-Glucosidase-IN-35 (0.01-1 mg/mL) in phosphate buffer (pH 6.8, 100 mM) at 37degC for 10-15 minutes. The substrate p-nitrophenyl-alpha-D-glucopyranoside (pNPG, 5 mM) is added to initiate the reaction in a total volume of 200 uL. After incubation for 20-30 minutes at 37degC, the reaction is terminated by adding sodium carbonate solution (Na2CO3, 1 M, 100 uL). The amount of released p-nitrophenol is measured spectrophotometrically at 405 nm using a microplate reader. The percentage of enzyme inhibition is calculated relative to control wells without inhibitor (containing DMSO vehicle). IC50 values are determined by fitting dose-response curves using non-linear regression analysis. The reported IC50 is 0.169 mg/mL. Each assay is typically performed in triplicate. Acarbose is used as a positive control.
|
| Cell Assay |
No published cell-based assays for alpha-Glucosidase-IN-35. For potential cellular studies, Caco-2 human intestinal epithelial cells can be used as a model for intestinal alpha-glucosidase inhibition. Caco-2 cells are cultured in DMEM supplemented with 10% fetal bovine serum, 1% non-essential amino acids, and antibiotics. Cells are seeded in 96-well plates and grown to confluence for 14-21 days to allow differentiation, during which they express brush border alpha-glucosidases and other enterocyte markers. Differentiated cells are treated with alpha-Glucosidase-IN-35 (0.05-1 mg/mL) in serum-free medium for 30-60 minutes at 37degC. After treatment, maltose (10 mM) or sucrose (10 mM) is added as substrate and incubated for an additional 30-60 minutes. Glucose produced from disaccharide hydrolysis is measured in the supernatant using a glucose oxidase-peroxidase (GOD-POD) colorimetric assay kit. Cell viability is assessed by MTT or LDH assay to ensure that observed effects are not due to cytotoxicity. The chromene structure suggests potential cellular permeability, making cell-based studies feasible.
|
| Animal Protocol |
No published in vivo animal study for alpha-Glucosidase-IN-35. Based on its potent alpha-glucosidase inhibitory activity, a potential in vivo protocol would involve oral administration of alpha-Glucosidase-IN-35 to male ICR mice (20-30 g) or Sprague-Dawley rats. The compound is formulated in 0.5% carboxymethylcellulose (CMC-Na) or 10% DMSO in saline. A typical dosing range would be 10-100 mg/kg, administered by oral gavage 30 minutes before an oral sucrose load (2 g/kg). Blood samples are collected from the tail vein at 0, 30, 60, and 120 minutes post-sucrose administration. Blood glucose levels are measured using a glucometer or enzymatic glucose assay kit (GOD-POD). The area under the curve (AUC) for blood glucose is calculated for 0-120 minutes. Reduction in AUC compared to vehicle-treated control indicates in vivo alpha-glucosidase inhibition. The oral glucose tolerance test (OGTT) using glucose (2 g/kg) can also be performed to assess non-specific effects. This protocol has not been validated for this specific compound.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data for alpha-Glucosidase-IN-35. As a small chromene (MW 218.25, LogP 2.78), the compound is relatively lipophilic and is expected to have good oral absorption following administration. The chromene scaffold is known to have favorable drug-like properties. Metabolism would likely occur in the liver via phase I (oxidation, demethylation) and phase II (glucuronidation, sulfation) enzymes. Plasma half-life, Cmax, AUC, clearance, protein binding, and tissue distribution have not been determined. Solubility: soluble in DMSO (typical solubility for chromenes). In vivo formulation options include 10% DMSO + 40% PEG300 + 5% Tween80 + 45% saline or 10% DMSO + 90% corn oil. Storage: powder at -20degC for 3 years.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for alpha-Glucosidase-IN-35. As a naturally occurring chromene isolated from Brickellia cavanillesii (a plant used in traditional medicine), the compound is expected to have low acute toxicity. Chromenes are a class of compounds known for diverse biological activities and generally favorable safety profiles. However, systematic toxicological studies have not been performed. For research use, standard laboratory safety precautions (gloves, lab coat, eye protection) should be followed. Avoid inhalation, skin contact, and ingestion. Dispose of according to hazardous waste regulations. Not for human use.
|
| References | |
| Additional Infomation |
1-(5-hydroxy-2,2-dimethylchromene-6-yl) ethyl ketone has been reported in Leucoblepharis subsessilis and Brickellia cavanillesii, and relevant data are available for reference.
alpha-Glucosidase-IN-35 (compound 1, CAS: 24672-84-2) is a naturally occurring chromene isolated from the aqueous extract of the aerial parts of Brickellia cavanillesii (Asteraceae). The compound demonstrates potent alpha-glucosidase inhibitory activity with an IC50 value of 0.169 mg/mL (approximately 775 uM). It is also known as 1-(5-hydroxy-2,2-dimethylchromen-6-yl)ethanone and has been reported with data available in PubChem (CID: 827487). alpha-Glucosidase-IN-35 is a valuable research tool for studying alpha-glucosidase inhibition, postprandial hyperglycemia, and anti-diabetic mechanisms. Molecular formula: C13H14O3, molecular weight: 218.25. Appearance: solid at room temperature. Solubility: soluble in DMSO. Storage: powder at -20degC for 3 years; in solvent at -80degC for 6 months. Not approved for clinical use. Reference: Sonia Escandon-Rivera, et al. alpha-Glucosidase Inhibitors from Brickellia cavanillesii. J Nat Prod. 2012;75(5). |
| Molecular Formula |
C13H14O3
|
|---|---|
| Molecular Weight |
218.25
|
| Exact Mass |
218.094
|
| CAS # |
24672-84-2
|
| PubChem CID |
827487
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.779
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
16
|
| Complexity |
319
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C1C=CC2OC(C=CC=2C=1O)(C)C)=O
|
| InChi Key |
GHZRKUIAWAOWRH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H14O3/c1-8(14)9-4-5-11-10(12(9)15)6-7-13(2,3)16-11/h4-7,15H,1-3H3
|
| Chemical Name |
1-(5-hydroxy-2,2-dimethylchromen-6-yl)ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5819 mL | 22.9095 mL | 45.8190 mL | |
| 5 mM | 0.9164 mL | 4.5819 mL | 9.1638 mL | |
| 10 mM | 0.4582 mL | 2.2910 mL | 4.5819 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
